As muscular dystrophy drug meets key goal, Italfarmaco plans march forward to regulators

As muscular dystrophy drug meets key goal, Italfarmaco plans march forward to regulators

Source: 
MedCity News
snippet: 

A Duchenne muscular dystrophy drug candidate from Italfarmaco Group has encouraging preliminary data from a pivotal study. The Milan, Italy-based pharmaceutical company says it now plans to meet with U.S. and European authorities about seeking regulatory approval for the small molecule.